Medication info
Lureka OD Tablet 50 mg (Pregabalin)

Lureka OD Tablet 50 mg (Pregabalin)

Prescription medicationOrally disintegrating Tablet
Ingredient · strength
Pregabalin›50mg / 1 tablet
Manufacturer / importer
Huons Life Science Co., Ltd.
Appearance
Yellow round orally disintegrating tablet
Packaging
30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]
Approval status
Active

MFDS item code 202600534 · Approved 2026.02.24

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
Who uses it
Adults · Children
Adult dosage
Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. Place the tablet on the tongue and, once it disintegrates, swallow without water. 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day); depending on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with renal impairment Because this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, administer a supplemental dose promptly after each 4-hour hemodialysis session. Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Huons Life Science Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is effective for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunct to control partial seizures in patients with epilepsy. Additionally, it helps in alleviating symptoms of fibromyalgia. It is used to improve symptoms of various neurological disorders.

Dosage and Administration

Adult dosage

Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. Place the tablet on the tongue and, once it disintegrates, swallow without water. 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day); depending on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with renal impairment Because this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, administer a supplemental dose promptly after each 4-hour hemodialysis session. Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so you should consult your healthcare provider immediately if you notice any mood changes or behavioral abnormalities during treatment. Patients allergic to pregabalin or any components of this medication should not take it. Diabetic patients may experience weight gain when taking this medication, which may require adjustment of their blood sugar control medication. If symptoms of angioedema, such as swelling of the face or around the mouth, occur, stop taking immediately and inform your healthcare provider. Elderly patients may experience dizziness, drowsiness, or confusion when taking this medication and should take precautions, avoiding dangerous activities until they acclimate to the effects of the new medication. Transient blurred vision or changes in vision may occur, and these symptoms can improve after discontinuing the medication. There is insufficient research on the safety and efficacy of this medication if other antiepileptic drugs are discontinued before its use, so careful consideration is warranted. Abrupt discontinuation of the medication may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so it is safe to taper off the medication gradually in consultation with your healthcare provider. Patients with a history of substance abuse may have an increased risk of misuse with this medication, so it should be administered carefully, and signs of substance abuse should be closely monitored. Patients with impaired kidney function may require dose adjustments of this medication. Patients with heart disease, especially those with congestive heart failure, require careful monitoring while taking this medication. When taken with opioid analgesics, respiratory depression may increase due to enhanced central nervous system depressant effects, warranting caution. In early pregnancy, there may be a risk of congenital malformations for the fetus; therefore, pregnant women should avoid taking this medication as much as possible, and women of childbearing age should use effective contraception. Breastfeeding women should discuss the use of this medication with their healthcare providers, as it may be excreted in breast milk. This medication may cause dizziness and drowsiness, so it is advisable to avoid driving or operating hazardous machinery after taking it. Severe skin reactions may rarely occur, so if any skin abnormalities develop, discontinue the medication immediately and inform your healthcare provider. Overdose may result in drowsiness, confusion, depression, seizures, and treatment such as blood dialysis may be required if necessary. Children and elderly individuals should store this medication in a safe place out of reach of children.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral edema, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in eyesight, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal ideation, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, appetite suppression, hypoglycemia, confusion, spatial disorientation, irritability, depression, elation, decreased libido, insomnia, depersonalization, sexual arousal disorder, restlessness, anxiety, mood swings, emotional decline, emotional elevation, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, ataxia, abnormal motor coordination, balance disorders, amnesia, attention deficit, memory impairment, tremors, speech disturbance, sensory abnormalities, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, language disorders, myoclonic jerks, reflex reduction, motor abnormalities, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, tremor at rest, syncope, confusion, hypokinesia, olfactory dysregulation, loss of taste, writing difficulties, blurred vision, diplopia, loss of peripheral vision, visual field defects, photopsia, dry eyes, conjunctival swelling, reduced vision, eye pain, eye fatigue, increased tear secretion, ocular irritation, mydriasis, perceptual depth changes during vibration, strabismus, visual brightness, vertigo, auditory hypersensitivity, first-degree heart block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, vomiting, abdominal bloating, constipation, dry mouth, abdominal distension, hypersalivation, gastroesophageal reflux, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, hives, diaphoresis, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falls, feeling of intoxication, sensory abnormalities, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, alanine aminotransferase increase, serum creatine phosphokinase increase, aspartate aminotransferase increase, blood sugar increase, platelet count decrease, potassium level decrease, weight loss, serum creatinine increase, white blood cell count decrease, hypersensitivity, allergic reactions, headache, loss of consciousness, mental disorders, keratitis, congestive heart failure, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, drowsiness, confusion state, depression, agitation, restlessness, seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain room temperature between 1 degree and 30 degrees Celsius. Proper storage will ensure the safety and effectiveness of the medication.

Appearance and packaging

Appearance

Yellow round orally disintegrating tablet

Package unit

30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.